BullFrog AI develops an artificial intelligence platform that utilizes causal AI and graph-based analytics to identify drug targets driving complex diseases. The company aims to reduce the time and cost of drug development while improving the success rate of new therapeutics.
Funding
$3.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The traditional drug discovery process is lengthy, expensive, and has a high failure rate, often due to ineffective target selection for complex diseases. Identifying the right drug targets from vast amounts of biological data remains a significant challenge.
Solution
BullFrog AI offers an AI-driven platform that leverages causal AI and graph-based analytics to enhance drug target identification. The platform models complex biological systems to provide functional evaluations and predictions of genetic influences on cellular behavior. By using advanced AI/ML techniques, BullFrog AI aims to accelerate R&D, reduce costs, and improve the success rate of new therapeutics. The company's approach focuses on identifying drug targets that directly drive disease mechanisms, leading to more effective drug development.
Target Audience
The primary audience includes pharmaceutical companies, biotechnology firms, and research institutions involved in drug discovery and development.
Features
- Causal AI and graph-based analytics for modeling complex biological systems
- Functional evaluations and predictions of genetic influences on cellular behavior
- Identification of novel drug targets driving disease
- AI/ML models to improve drug target selection